0001553350-26-000089
SEC filingRevenue accelerated 185% to $2.7K amid persistent operating losses widening to -$1.8M, driven by test utilization growth but pressured by rising R&D personnel and overhead expenses in a pre-scale biotech with long sales cycles.
Cardio Diagnostics achieved a 185% year-over-year revenue increase to $2.7K from $940 in Q1 FY2026. This growth stems from customers being charged for tests utilized or minimum committed volumes, with pricing varying by organization type, size, and volume. The acceleration signals early commercial traction in cardiovascular diagnostics, though absolute levels remain modest. Management notes long sales and partnership cycles persist, so investors should track if volume commitments convert to sustained topline expansion.
Operating loss expanded 9.5% to -$1.8M from -$1.6M, driven primarily by higher software and web computing fees, investor relations expenses, annual franchise taxes, and corporate overhead. These increases reflect the costs of building operational infrastructure in a pre-revenue scale biotech. Net income followed suit, widening 9.4% to -$1.8M. Such G&A pressures are common as companies invest in visibility and compliance ahead of broader commercialization.
Research and development expenses rose due to increased personnel in 2026, contributing to overall loss expansion. This headcount growth underscores commitment to advancing the diagnostic platform, essential for differentiating in cardiovascular testing. While it intensified cash burn, it positions the company to potentially accelerate adoption through innovative offerings, even as sales cycles remain extended.
Diluted EPS narrowed 35% to -$0.63 from -$0.97, reflecting modestly better per-share loss control despite higher absolute losses. This improvement highlights operational progress in containing the rate of loss growth relative to the expanded share base, providing a positive signal for shareholders monitoring path to breakeven.